Actively Recruiting
High Resolution Anuscopy Study
Led by Universitair Ziekenhuis Brussel · Updated on 2025-02-19
500
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Anal squamous cell carcinoma (SCC) is mostly caused by infection with high-risk human papillomavirus (HPV). Although anal SCC is rare in the general population, certain high-risk groups are affected more often. These groups are screened using anal swabs to check for abnormal cells and high-risk HPV. Referral for high resolution anoscopy (HRA) is advised when abnormal results are found. HRA is the only method to detect precancerous lesions in the anal canal but requires specialized expertise. This observational study at Universitair Ziekenhuis Brussel involves collecting and analyzing data on HPV infection and its link to anal disease. Participants include patients who have had or will be referred for HRA at this center. The study aims to explore the prevalence of precancerous lesions among different risk groups, such as men who have sex with men using PrEP or living with HIV. It also examines associations between abnormal tissue findings, patient characteristics, and HPV infection patterns over an average of 5 years. Participants will undergo HRA as part of their care, and data from these procedures will be studied. Researchers will measure the prevalence of precancerous lesions, abnormal histology, and anal cancer in these at-risk populations. The study will also correlate abnormal tissue and cell findings with HPV infection status. Participation involves data collection through routine clinical care without additional interventions. The study continues until 2029, providing long-term insights into anal cancer risks and HPV-related changes.
CONDITIONS
Brief Title
High Resolution Anuscopy Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients who have undergone or will be referred for high resolution anoscopy (HRA) at UZ Brussel
- 18 years or older
- Able to understand and communicate in French, Dutch, or English
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Through study completion, on average 5 years
Participants undergo high resolution anoscopy (HRA) to evaluate anal conditions such as precancerous lesions.
1 or more visits for HRA depending on clinical need
Duration - Through study completion, on average 5 years
Participants are monitored over time to assess the prevalence and progression of precancerous lesions and anal cancer in at-risk populations.
Periodic visits over 5 years
Trial Site Locations
Total: 1 location
1
UZ Brussel
Jette, Belgium, 1090
Actively Recruiting
Research Team
M
Magali Surmont
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here